Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
45–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female subjects from 45 to 85 years of age
Definite IPF within 3 years prior to screening
Be able to walk at least 50 meters
You may not be if
Significant diseases other than IPF
Obstructive lung disease
Aortic aneurysm greater than or equal to 3.5 cm in diameter
Treatment with immunosuppressive, cytotoxic, or antifibrotic drugs \< 28 days prior to randomization are not permitted.
* N-acetylcysteine is permitted provided the individual has been on a stable dose for \> 4 weeks prior to screening
* Concomitant use of pirfenidone or nintedanib must be in accordance with the approved prescribing instructions in the country where the site is located
Individuals actively listed for lung transplant are excluded. However individuals at transplant centers with long waiting times (greater than 1 year) may be permitted to enter the study after discussion with Medical Monitor.
Clareo Health | Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)
